ENAapplication/xmlftp.sra.ebi.ac.uk/vol1/fastq/SRR115/025/SRR11529125/SRR11529125.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR115/049/SRR11529349/SRR11529349.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR115/048/SRR11529348/SRR11529348.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR115/050/SRR11529350/SRR11529350.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR115/026/SRR11529126/SRR11529126.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR115/027/SRR11529127/SRR11529127.fastq.gzprimaryOK200GenomicsInstitute of Medicinal Biotechnology, Chinese Academy of Medical Scienceshttps://www.ebi.ac.uk/ena/browser/view/PRJNA624813Norvancomycin has been widely used in clinic to against Gram-positive bacteria, especially MRSA (Methicillin-resistant Staphylococcus aureus) and MRSE (methicillin-resistant Staphylococcus epidermidis) in China. Amycolatopsis orientalis NCPC 2-48, a high yield strain derived from Amycolatopsis orientalis CPCC200066, has been used for industrial large-scale production of the vital antibiotic norvancomycin by the North China Pharmaceutical Company. Here we sequenced and compared the transcriptomes of CPCC200066 and NCPC 2-48, to identify high yield mechanism potentially involved in the norvancomycin biosynthetic pathway.ENASprain, Strain., Strains, Sprains, Strains and Sprains0.00.00.00.00.0falseTranscriptomics profiling at norvancomycin producing strains2022-05-122021-01-01PRJNA62481331958